In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response.
Aditi SahuKivanc KoseLukas KraehenbuehlCandice ByersAliya HollandTeguru TemboAnthony SantellaAnabel AlfonsoMadison LiMiguel CordovaMelissa GillChristi FoxSalvador GonzalezPiyush KumarAmber Weiching WangNicholas R KurtanskyPratik ChandraniShen YinParas MehtaCristian Navarrete-DechentGary PetersonKimeil KingStephen W DuszaNing YangShuaitong LiuWilliam PhillipsPascale GuiteraAnthony RossiAllan HalpernLiang DengMelissa PulitzerAshfaq MarghoobChih-Shan Jason ChenTaha MerghoubMilind RajadhyakshaPublished in: Nature communications (2022)
Response to immunotherapies can be variable and unpredictable. Pathology-based phenotyping of tumors into 'hot' and 'cold' is static, relying solely on T-cell infiltration in single-time single-site biopsies, resulting in suboptimal treatment response prediction. Dynamic vascular events (tumor angiogenesis, leukocyte trafficking) within tumor immune microenvironment (TiME) also influence anti-tumor immunity and treatment response. Here, we report dynamic cellular-level TiME phenotyping in vivo that combines inflammation profiles with vascular features through non-invasive reflectance confocal microscopic imaging. In skin cancer patients, we demonstrate three main TiME phenotypes that correlate with gene and protein expression, and response to toll-like receptor agonist immune-therapy. Notably, phenotypes with high inflammation associate with immunostimulatory signatures and those with high vasculature with angiogenic and endothelial anergy signatures. Moreover, phenotypes with high inflammation and low vasculature demonstrate the best treatment response. This non-invasive in vivo phenotyping approach integrating dynamic vasculature with inflammation serves as a reliable predictor of response to topical immune-therapy in patients.